Research Article | Open Access
Chao Zhang, Gui-hua Hou, Jian-kui Han, Jing Song, Ting Liang, "Radioiodine Labeled Anti-MIF McAb: A Potential Agent for Inflammation Imaging", Mediators of Inflammation, vol. 2007, Article ID 050180, 5 pages, 2007. https://doi.org/10.1155/2007/50180
Radioiodine Labeled Anti-MIF McAb: A Potential Agent for Inflammation Imaging
Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine that may play a role in the pathogenesis of inflammation. Radiolabeled anti-MIF McAb can be used to detect in vivo inflammatory changes. The objective of this study was to investigate in vivo biology of radioiodinated anti-MIF McAb using the inflammation model mice. Anti-MIF McAb was radioiodinated with Na125I by Iodogen method. Animal models were induced in the mice by intramuscular injection of S. aureus, E. coli, and turpentine oil. The biodistribution studies with radioiodinated anti-MIF McAb were performed on inflammation mice. The relationship between inflammatory lesions and anti-MIF McAb binding was investigated using the percent of injected dose per gram tissue (% ID/g) of tissue samples and whole-body autoradiography. The radioactivity of 125I-anti-MIF McAb in the inflammatory tissue increased gradually for three inflammation models. The highest uptake was found in S. aureus group and the lowest was in E. coli group. The uptake in turpentine oil group was average. Whole-body autoradiography showed that all inflammation foci could be visualized clearly from 24 hours after injection, but 48 hours images were much clearer in accordance with the high T/NT ratio. These results demonstrate the ability of radioiodinated anti-MIF McAb to measure in vivo inflammatory events represented by high expression of MIF and suggests that radiolabeled anti-MIF McAb warrants further investigation as a potential inflammation-seeking agent for imaging to detect inflammatory disorders.
- B. R. Bloom and B. Bennett, “Mechanism of a reaction in vitro associated with delayed-type hypersensitivity,” Science, vol. 153, no. 3731, pp. 80–82, 1966.
- J. R. David, “Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 56, no. 1, pp. 72–77, 1966.
- J. Bernhagen, T. Calandra, R. A. Mitchell et al., “MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia,” Nature, vol. 365, no. 6448, pp. 756–759, 1993.
- C. M. Denkinger, C. Metz, G. Fingerle-Rowson, M. D. Denkinger, and T. G. Forsthuber, “Macrophage migration inhibitory factor and its role in autoimmune diseases,” Archivum Immunologiae et Therapiae Experimentalis, vol. 52, no. 6, pp. 389–400, 2004.
- T. Calandra and T. Roger, “Macrophage migration inhibitory factor: a regulator of innate immunity,” Nature Reviews Immunology, vol. 3, no. 10, pp. 791–800, 2003.
- E. Lolis, “Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery,” Current Opinion in Pharmacology, vol. 1, no. 6, pp. 662–668, 2001.
- Y. P. De Jong, A. C. Abadia-Molina, A. R. Satoskar et al., “Development of chronic colitis is dependent on the cytokine MIF,” Nature Immunology, vol. 2, no. 11, pp. 1061–1066, 2001.
- F. A. Bozza, R. N. Gomes, A. M. Japiassú et al., “Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis,” Shock, vol. 22, no. 4, pp. 309–313, 2004.
- T. Ohkawara, J. Nishihira, H. Takeda et al., “Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice,” Gastroenterology, vol. 123, no. 1, pp. 256–270, 2002.
- Y. Sakai, A. Masamune, A. Satoh, J. Nishihira, T. Yamagiwa, and T. Shimosegawa, “Macrophage migration inhibitory factor is a critical mediator of severe acute pancreatitis,” Gastroenterology, vol. 124, no. 3, pp. 725–736, 2003.
- M. Leech, C. Metz, P. Hall et al., “Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1601–1608, 1999.
- N. Yabunaka, J. Nishihira, Y. Mizue et al., “Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes,” Diabetes Care, vol. 23, no. 2, pp. 256–258, 2000.
- F. Nicoletti, A. Créange, D. Orlikowski et al., “Macrophage migration inhibitory factor (MIF) seems crucially involved in Guillain-Barré syndrome and experimental allergic neuritis,” Journal of Neuroimmunology, vol. 168, no. 1-2, pp. 168–174, 2005.
- M. Niino, A. Ogata, S. Kikuchi, K. Tashiro, and J. Nishihira, “Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet’s disease,” Journal of the Neurological Sciences, vol. 179, no. 1-2, pp. 127–131, 2000.
- C. J. van der Laken, O. C. Boerman, W. J. G. Oyen, M. T. P. van de Ven, J. W. M. van der Meer, and F. H. M. Corstens, “Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction,” European Journal of Nuclear Medicine, vol. 25, no. 5, pp. 535–546, 1998.
- W. Becker, “The contribution of nuclear medicine to the patient with infection,” European Journal of Nuclear Medicine, vol. 22, no. 10, pp. 1195–1211, 1995.
- S. Vinjamuri, A. V. Hall, K. K. Solanki et al., “Comparison of infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection,” Lancet, vol. 347, no. 8996, pp. 233–235, 1996.
- E. P. Krenning, D. J. Kwekkebomm, S. Pauwels, L. K. Kvols, and J. C. Reubi, “Somatostatin receptor scintigraphy,” in Nuclear Medicine Annual, pp. 1–50, Raven Press, New York, NY, USA, 1995.
- M. R. Plucher and P. J. Blower, “Labelling of lekocytes with colloidal tecnetium-99m-Sn: an investigation of the labeling process by autoradiography,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 22, no. 2, pp. 101–107, 1995.
- G. Ferro-Flores, C. Arteaga de Murphy, M. Pedraza-López et al., “In vitro and in vivo assessment of -UBI specificity for bacteria,” Nuclear Medicine and Biology, vol. 30, no. 6, pp. 597–603, 2003.
- G. W. Visser, R. P. Klok, J. W. K. Gebbinck, T. Ter Linden, G. A. van Dongen, and C. F. Molthoff, “Optimal quality -monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 509–519, 2001.
- G. C. Jayson, J. Zweit, A. Jackson et al., “Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies,” Journal of the National Cancer Institute, vol. 94, no. 19, pp. 1484–1493, 2002.
- I. Verel, G. W. M. Visser, R. Boellaard et al., “Quantitative immuno-PET for in vivo scouting of -labeled monoclonal antibodies in xenograft-bearing nude mice,” Journal of Nuclear Medicine, vol. 44, no. 10, pp. 1663–1670, 2003.
- E. F. Morand, “New therapeutic target in inflammatory disease: macrophage migration inhibitory factor,” Internal Medicine Journal, vol. 35, no. 7, pp. 419–426, 2005.
- D. Aeberli, M. Leech, and E. F. Morand, “Macrophage migration inhibitory factor and glucocorticoid sensitivity,” Rheumatology, vol. 45, no. 8, pp. 937–943, 2006.
Copyright © 2007 Chao Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.